A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
A legfontosabb adatok
- Hol
- Atlanta, Brandon, Charlotte, Cincinnati, Colombia, Dallas, Frisco, Lansing, Macon, Miami, San Antonio, Spokane, St Louis, Sugar Land és Winter Park (Egyesült Államok)Mind a 15 helyszín megnézése
- Fázis
- 3. fázis
Neked szólhat?
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 70 év között vagy?
Forrás: NCT07540897: ki vehet részt
Helyszínek itt: Egyesült Államok
- Atlanta, GeorgiaHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
- Brandon, FloridaHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
- Charlotte, North CarolinaHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
- Cincinnati, OhioHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
- Colombia, South CarolinaHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
- Dallas, TexasHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
- Frisco, TexasHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
- Lansing, MichiganHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
- Macon, GeorgiaHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
- Miami, FloridaHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
- San Antonio, TexasHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
- Spokane, WashingtonHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
- St Louis, MissouriHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
- Sugar Land, TexasHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
- Winter Park, FloridaHospital not named in the registryContact: Director, Clinical Trial ManagerRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Alkermes, Inc.
- Azonosító
- NCT07540897
- A regiszteradat frissítve
- 2026. október 7.
- Eredeti leírás
The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.A teljes eredeti leírásKevesebb
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 Study 304)
The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.
Bevonási feltételek: Meets the diagnostic criteria of NT1 according to ICSD-3-TR guidelines, confirmed by diagnostic evaluations (either PSG/MSLT* or CSF hypocretin-1 level).
Kizáró feltételek: Is currently enrolled in another interventional clinical trial or has received any investigational drug or used any interventional investigational device within 30 days prior to Visit 1. Participants previously enrolled in Study ALKS 2680-201 are not eligible for enrollment; Has another comorbid sleep disorder or condition that may influence the sleep-wake cycle; Has a history or presence at Visit 1 of other clinically significant (treated or untreated) illness, disease, abnormality, or surgical procedure that, in the opinion of the Investigator, might compromise participant safety, interfere with any study assessment, or affect the participant's ability to complete the study; Is currently pregnant, breastfeeding, or is planning to become pregnant during the study.